Overview

Quest Diagnostics is an American clinical laboratory company that provides diagnostic information services to physicians, hospitals, health systems, employers, insurers, government programs, and consumers. Its testing portfolio spans routine blood and urine analysis, infectious-disease testing, cancer diagnostics, cardiovascular testing, neurological and genetic testing, pathology, toxicology, drug monitoring, and specialized testing for kidney disease and dialysis care. The company operates a large national network of patient service centers and laboratories, supplemented by hospital and health-system relationships and consumer-directed services. The business originated in 1967 as Metropolitan Pathology Laboratory, founded by physician Paul A. Brown. It became MetPath in 1969 and was acquired by Corning Glass Works in 1982, after which it operated as Corning Clinical Laboratories. Quest Diagnostics became an independent public company on December 31, 1996, when Corning spun off its clinical laboratory operations. The separation established the modern Quest identity and enabled the company to expand through acquisitions, partnerships, hospital outreach arrangements, and new testing channels. During the late 1990s, Quest acquired or integrated several laboratory operations, including a division of Diagnostic Medical Laboratory and SmithKline Beecham Clinical Laboratories. It also formed Sonora Quest Laboratories with Banner Health to serve Arizona. In 2007, the company expanded its diagnostic capabilities through the acquisition of AmeriPath, a provider focused on anatomic pathology and related services. Later agreements with health systems, retailers, insurers, and technology companies broadened access to its testing infrastructure. Quest's business model combines high-volume routine testing with specialized diagnostic services. Physicians and hospitals use its laboratories for clinical decision support, while employers and public agencies use the company for occupational, forensic, and court-ordered drug testing. QuestDirect, introduced in 2018, allows consumers to initiate selected laboratory tests without first arranging the order through a traditional physician visit, subject to applicable regulatory and clinical requirements. The company also developed a substantial COVID-19 testing operation during the pandemic, performing millions of molecular and serology tests in 2020. The brand is positioned around scale, geographic accessibility, laboratory expertise, and the practical use of diagnostic data in healthcare decisions. Its operations are primarily concentrated in the United States, with additional activity in Puerto Rico, Mexico, and Brazil and collaborative relationships involving healthcare organizations in other countries. Quest moved its headquarters from Madison, New Jersey, to Secaucus in 2018. More recent expansion has included Alzheimer's blood biomarker testing through the AD-Detect line and the acquisition of selected Spectra Laboratories assets from Fresenius Medical Care in 2025, strengthening services related to dialysis and end-stage kidney disease. Quest has also faced significant regulatory and reputational challenges. It paid substantial settlements concerning allegations involving faulty testing products, Medicare billing, Medi-Cal overcharges, and provider incentives. Its testing was among the laboratory work examined in Ireland's CervicalCheck controversy, and a breach involving a third-party collections provider exposed information associated with some Quest patients. These events illustrate the compliance, quality-control, privacy, and reimbursement risks inherent in large-scale diagnostic services. Despite these issues, Quest remains one of the largest clinical laboratory organizations in the United States and an important infrastructure provider for routine and specialized medical testing.

History

Quest Diagnostics traces its origins to Metropolitan Pathology Laboratory, established in 1967 by Paul A. Brown, MD. The laboratory changed its name to MetPath in 1969 and built its base in Teaneck, New Jersey. In 1982, Corning Glass Works acquired MetPath and renamed the operation Corning Clinical Laboratories. Under Corning, the laboratory business developed into a substantial provider of clinical testing and related services. On December 31, 1996, Corning spun off its clinical laboratory operations, creating Quest Diagnostics as an independent company. Kenneth W. Freeman was appointed chief executive during the transition. Quest pursued expansion soon afterward, acquiring a laboratory division of Diagnostic Medical Laboratory in 1997 and adding SmithKline Beecham Clinical Laboratories in 1999. The latter transaction included interests associated with CompuNet Clinical Laboratory and a medical sample transportation operation. In 1997, Quest and Banner Health also created Sonora Quest Laboratories, a joint venture serving Arizona. The company continued to broaden its geographic and clinical reach in the 2000s. Quest formed a strategic alliance with Ciphergen Biosystems in 2005 to commercialize proteomic tests and acquired AmeriPath in 2007, strengthening its pathology business. From 2004 to 2012, Surya Mohapatra served as president and chief executive officer. Stephen Rusckowski, previously associated with Philips Healthcare, succeeded him and led Quest through a period of network development, health-system cooperation, and consumer-access initiatives. Quest and UMass Memorial Health Care subsequently worked together to acquire a clinical outreach laboratory serving central New England. From the middle of the 2010s onward, Quest experimented with new points of access. A 2016 collaboration with Safeway introduced testing services in selected stores across several states, while a later Walmart relationship brought laboratory testing to selected stores in Texas and Florida. The company also reached an agreement to become an in-network laboratory provider for UnitedHealthcare beginning in 2019. In September 2018, Quest relocated its headquarters from Madison, New Jersey, to Secaucus. That November, it launched QuestDirect, a consumer-initiated testing service for selected health and wellness tests. The COVID-19 pandemic made Quest's laboratory infrastructure especially visible. In March 2020, the company introduced COVID-19 testing, including molecular and serology services, and reported processing millions of tests during the year. Its broader portfolio continued to include testing for cancer, cardiovascular disease, infectious diseases, neurological conditions, genetic disorders, employment screening, and court-ordered drug testing. Quest has expanded into newer biomarker and specialty areas. In 2024, it added a pTau-217 blood screening option to its AD-Detect Alzheimer's-related product line. In February 2025, it acquired selected assets of Fresenius Medical Care's Spectra Laboratories and entered a separate arrangement to provide laboratory and clinical testing services related to dialysis and end-stage kidney disease. The company's history also includes substantial compliance and quality controversies. In 2009, Quest paid $302 million to settle federal allegations concerning faulty medical testing kits. In 2011, it paid $241 million to resolve California allegations involving Medi-Cal overcharges and improper provider incentives. Quest testing was later examined in Ireland's CervicalCheck controversy over inaccurate cervical smear results. In 2019, Quest disclosed unauthorized access to information held by American Medical Collection Agency, a third-party collections provider connected through a contractor. These matters have made regulatory compliance, analytical quality, billing practices, and data security continuing issues for the brand. Today, Quest Diagnostics operates primarily in the United States, with operations or activities in Puerto Rico, Mexico, and Brazil and collaborative relationships with healthcare organizations elsewhere. Its identity is built around laboratory scale, broad test availability, patient-service-center convenience, and the conversion of diagnostic results into information used by clinicians, patients, employers, and public-health systems.

2025
Selected Spectra Laboratories assets are acquired
[1]Quest Diagnosticsen.wikipedia.org
Quest expands kidney-care and dialysis-related testing through selected assets acquired from Fresenius Medical Care's Spectra Laboratories.
2024
pTau-217 is added to AD-Detect
[1]Quest Diagnosticsen.wikipedia.org
Quest expands its Alzheimer's-related blood screening portfolio with pTau-217 testing.
2020
COVID-19 testing expands
[1]Quest Diagnosticsen.wikipedia.org
Quest launches COVID-19 molecular and serology testing and processes millions of tests during the pandemic.
2018
QuestDirect launches
[1]Quest Diagnosticsen.wikipedia.org
Quest introduces a consumer-initiated route to selected laboratory tests.
2007
AmeriPath is acquired
[1]Quest Diagnosticsen.wikipedia.org
The acquisition strengthens Quest's anatomic pathology and related diagnostic capabilities.
1999
SmithKline Beecham laboratory operations are added
[1]Quest Diagnosticsen.wikipedia.org
Quest expands through the acquisition of SmithKline Beecham Clinical Laboratories.
1997
Sonora Quest Laboratories is formed
[1]Quest Diagnosticsen.wikipedia.org
Quest and Banner Health create an Arizona laboratory joint venture.
1996
Quest Diagnostics becomes independent
[1]Quest Diagnosticsen.wikipedia.org
Corning spins off the clinical laboratory business on December 31, creating an independent Quest Diagnostics.
1982
Corning acquires the laboratory
[1]Quest Diagnosticsen.wikipedia.org
Corning Glass Works acquires MetPath and renames it Corning Clinical Laboratories.
1969
The business adopts the MetPath name
[1]Quest Diagnosticsen.wikipedia.org
Metropolitan Pathology Laboratory changes its name to MetPath and operates from Teaneck, New Jersey.
1967
Metropolitan Pathology Laboratory is founded
[1]Quest Diagnosticsen.wikipedia.org
Paul A. Brown, MD, establishes the laboratory business that later becomes Quest Diagnostics.

Products and positioning

A large-scale, accessible diagnostic information services provider emphasizing national laboratory capacity, convenience, test breadth, and clinical support.

Clinical diagnostics · 1967
Routine clinical laboratory testing
Quest's core offering includes high-volume blood, urine, and other specimen testing used for routine screening, diagnosis, treatment monitoring, and preventive care. Services are ordered through physicians, hospitals, health systems, and other authorized channels and are delivered through Quest laboratories and patient service centers.
Consumer health testing · 2018
QuestDirect
QuestDirect is a consumer-initiated testing service introduced in 2018. It allows customers to select certain health and wellness laboratory tests directly, after which specimens are collected through Quest's service network. Availability and test requirements vary by jurisdiction and product.
Neurological and Alzheimer's testing
AD-Detect
AD-Detect is Quest's Alzheimer’s-related testing line. In 2024, the company added a blood screening focused on the pTau-217 protein, extending the line beyond conventional laboratory offerings into biomarker-based assessment for neurological disease research and clinical evaluation.
Infectious-disease testing · 2020
COVID-19 testing
Quest introduced COVID-19 molecular and serology testing in 2020. The service supported pandemic diagnosis and antibody assessment and became one of the company's largest short-term testing programs, with millions of tests processed during the first year of widespread U.S. testing.
Pathology
Cancer and pathology diagnostics
Quest provides pathology and cancer-related testing, including analysis of tissue and other specimens used to characterize disease and guide treatment decisions. The company's pathology capabilities were strengthened by the 2007 AmeriPath acquisition and are delivered to physicians, hospitals, and health systems.
Toxicology and occupational health
Employer and forensic drug testing
Quest performs employment, workplace, forensic, and court-ordered drug testing. These services use toxicology and specimen-validation capabilities and serve employers, government bodies, courts, and other organizations requiring standardized testing programs.
Specialty diagnostics · 2025
Kidney and dialysis laboratory services
Following its 2025 transaction involving selected Spectra Laboratories assets, Quest expanded its specialty testing services for dialysis providers and patients with end-stage kidney disease. The offering supports clinical monitoring and laboratory needs associated with kidney-care programs.

Controversies

2026
Quest Diagnostics discloses unauthorized access to patient records
Quest Diagnostics disclosed that an unauthorized party accessed certain patient records in its Quanum Lab Services Manager system. The company said it was investigating the incident and had not determined the full scope. The disclosure concerned access to patient records within that system, and the company's statement described the matter as under investigation at the time. No further details on the extent of the access, the number of records involved, or the identity of the unauthorized party were provided in the announcement.
Source 1 Source 2
2021
Quest Diagnostics sued over workers’ compensation billing
A plaintiff sued Quest Diagnostics, alleging that the company directly billed a patient for workers’ compensation-related charges despite notice that the charges were work-related and authorization from the workers’ compensation insurer. The complaint alleges a violation of Florida’s Consumer Collection Practices Act.
Source
2019
Data exposure involving American Medical Collection Agency
Quest reported that American Medical Collection Agency had experienced unauthorized access to a system containing information received from multiple entities, including information associated with Quest through a contractor relationship. AMCA subsequently filed for bankruptcy.
Source
2018
CervicalCheck laboratory accuracy controversy
Quest was among laboratories examined in connection with inaccurate cervical smear testing for Ireland's CervicalCheck screening program. The issue generated audits, lawsuits, and a government inquiry.
Source
2011
California Medi-Cal false-claims settlement
Quest paid $241 million to settle California allegations that it overcharged the Medi-Cal program and provided improper incentives to encourage healthcare-provider use of its laboratories.
Source
2009
Federal settlement over faulty medical testing kits
Quest paid $302 million to the U.S. government to resolve allegations that it manufactured and distributed faulty medical testing kits. The settlement was described as the largest whistleblower-related settlement involving a medical laboratory and a faulty product at that time.
Source

Marketing campaigns

2017Walmart laboratory access partnership
Texas · Florida
Quest partnered with Walmart to incorporate laboratory testing into approximately 15 stores, extending the company's patient-access model into a major retail environment.
Outcome. Established testing at selected Walmart locations.
Source
2016Safeway retail testing collaboration
United States
Quest collaborated with Safeway to bring laboratory testing access to selected stores in California, Maryland, Virginia, Texas, and Colorado, testing a retail-oriented model for patient convenience.
Outcome. Expanded access in selected retail locations; broader outcome not specified in the reference material.
Source

Brand decisions

2025
Expand kidney-care testing through Spectra assetsM&A
Background
Dialysis and end-stage kidney disease require recurring, specialized laboratory monitoring.
Action taken
Quest acquired selected assets of Fresenius Medical Care's Spectra Laboratories and entered a separate agreement covering related clinical testing and laboratory services.
Aftermath
The transaction strengthened Quest's position in dialysis and kidney-disease laboratory services.
Source
2020
Scale COVID-19 molecular and serology testingProduct launch
Background
The COVID-19 pandemic created urgent demand for diagnostic testing at national scale.
Action taken
Quest launched COVID-19 molecular and serology services and expanded laboratory capacity to process large test volumes.
Aftermath
The company became a major U.S. testing provider during the pandemic and reported processing millions of tests in 2020.
Source
2018
Launch QuestDirectProduct launch
Background
Consumers were increasingly seeking direct and convenient access to health information and laboratory services.
Action taken
Quest introduced a consumer-initiated testing service for selected health and wellness tests.
Aftermath
Quest added a direct-to-consumer access channel alongside physician- and institution-ordered testing.
Source
2005
Form a proteomics testing alliance with Ciphergen BiosystemsStrategy
Background
Quest sought to commercialize newer diagnostic approaches based on proteomic analysis.
Action taken
The companies formed a strategic alliance to commercialize novel proteomic tests.
Aftermath
The alliance represented an effort to extend Quest beyond routine laboratory testing into emerging biomarker technologies.
Source
1996
Separate from Corning and operate independentlyStrategy
Background
Corning's clinical laboratory operations had developed into a substantial diagnostic business requiring an independent corporate structure.
Action taken
Corning spun off the business on December 31, 1996, creating independent Quest Diagnostics.
Aftermath
The separation gave Quest a standalone public-company identity and a platform for acquisitions and partnerships.
Source

Recent events

2025
Quest acquires selected Spectra Laboratories assets[1]Quest Diagnosticsen.wikipedia.org
M&A
Quest acquired selected assets from Fresenius Medical Care's Spectra Laboratories and separately agreed to provide testing services associated with dialysis and end-stage kidney disease.
2024
Quest adds pTau-217 blood screening to AD-Detect[1]Quest Diagnosticsen.wikipedia.org
Product launch · Product generation
The company expanded its Alzheimer's-related testing line with a blood test intended to analyze the pTau-217 biomarker.
2022
Quest Diagnostics announces leadership transition[7]Quest Diagnostics announces leadership transitionir.questdiagnostics.com
Leadership change
Jim Davis succeeded Stephen Rusckowski as chief executive officer and chairman, marking a planned leadership transition at the public company.
2020
Quest announces COVID-19 testing service[1]Quest Diagnosticsen.wikipedia.org
Product launch · Other
Quest launched molecular and serology testing during the COVID-19 pandemic and reported performing millions of tests that year.
2020
Quest Diagnostics becomes a major commercial COVID-19 testing provider[8]Quest Diagnostics becomes a major commercial COVID-19 testing providerir.questdiagnostics.com
Product launch · Other
During the COVID-19 pandemic, Quest expanded molecular and antibody testing capacity and processed substantial volumes of SARS-CoV-2 tests for healthcare and public-health customers.
2018
Quest becomes an in-network laboratory provider for UnitedHealthcare[1]Quest Diagnosticsen.wikipedia.org
Other
Quest announced an agreement to join UnitedHealthcare's laboratory network beginning in 2019, increasing covered-member access.
2018
Quest launches consumer-initiated QuestDirect testing[1]Quest Diagnosticsen.wikipedia.org
Product launch
QuestDirect introduced a route for consumers to purchase selected health and wellness laboratory tests directly.
2017
Quest and Walmart expand retail laboratory access[1]Quest Diagnosticsen.wikipedia.org
Campaign
Quest partnered with Walmart to provide laboratory testing at approximately 15 locations in Texas and Florida.
2016
Quest and Safeway place laboratory services in selected stores[1]Quest Diagnosticsen.wikipedia.org
Campaign · Other
The collaboration tested retail-based access to Quest diagnostic services in selected U.S. markets.
2007
Quest expands pathology capabilities through AmeriPath acquisition[1]Quest Diagnosticsen.wikipedia.org
M&A
Quest acquired AmeriPath, broadening its presence in anatomic pathology and physician-oriented diagnostic services.

Showing the 10 most recent.

Related entries

Celera Corporation